In addition, we searched for studies including persons at risk of developing TB after exposure to non-MDR-TB patients who were treated with anti-tuberculosis drugs other than isoniazid or rifampicin.
B A C K G R O U N D : Existing international guidelines provide different recommendations for the management of contacts of multidrug-resistant tuberculosis (MDR-TB) patients. O B J E C T I V E :
To conduct two systematic reviews with the aim of identifying chemoprophylactic approaches that are effective in contacts of MDR-TB patients to assist in policy making.
D E S I G N :
We systematically searched the Medline, Embase, Central, LILACS, TRIP and BIOSIS Preview databases for studies on the effectiveness of anti-tuberculosis drugs in preventing active TB in persons at risk of developing MDR-TB. This was done as an update of a systematic review from 2006 using the same methodology. In addition, we searched for studies including persons at risk of developing TB after exposure to non-MDR-TB patients who were treated with anti-tuberculosis drugs other than isoniazid or rifampicin.
R E S U LT S :
Of 1195 references assessed in the update, one additional study could be included. As the initial review included two studies, the total number of included studies equals three. One study reported no contacts who developed TB, whether or not they received prophylaxis. The other two studies showed non-significant risk differences of 4% (95%CI −3 to 12), and 5% (95%CI −2 to 11), both in favour of chemoprophylaxis. For the additional review, 2480 references were assessed, but none could be included.
C O N C L U S I O N :
The attention given to MDR-TB in recent years has not resulted in publications on preventive treatment for contacts of MDR-TB patients. The available evidence is not sufficient to support or reject preventive treatment. Furthermore, the combined available evidence is of very low quality. K E Y W O R D S : prevention; multidrug resistance; latent TB PREVENTIVE TREATMENT for contacts of tuberculosis (TB) patients is highly effective in both nonhuman immunodefi ciency virus (HIV) infected and HIV-infected persons. 1, 2 It is included in guidelines for TB control of, for example, the Centers for Disease Control and Prevention (CDC)/American Thoracic Society (ATS), 3 and the National Institute for Health and Clinical Excellence. 4 The evidence for this is mainly for isoniazid (INH) preventive treatment in drug-susceptible TB. In contrast, preventive treatment for contacts of INH and rifampicin (RMP) resistant, i.e., multidrug-resistant TB (MDR-TB), patients is controversial. In some guidelines, treatment with pyrazinamide (PZA) and ethambutol (EMB) or PZA and a quinolone (i.e., levofl oxacin or ofl oxacin) for 6-12 months is recommended for persons who are likely to be infected with MDR-TB and who are at high risk for developing active TB. 3 Other guidelines recommend that close contacts of MDR-TB patients should not be prescribed chemoprophylaxis but should receive careful clinical follow-up for a period of at least 2 years. 4, 5 An explanation for the difference in recommendations is that there is little evidence on the effectiveness of preventive treatment for contacts of MDR-TB patients: in other words, the guideline recommendations are not supported by sound and clear evidence. A systematic review by Fraser et al. concluded that evidence of the effects of treatment of latent tuberculosis infection (LTBI) in people exposed to MDR-TB is extremely limited in both quantity and quality. 6 Also, there are no randomised controlled trials comparing anti-tuberculosis drug regimens with an alternative anti-tuberculosis drug regimen, placebo or no intervention given to people exposed to MDR-TB to prevent active TB. 7 The World Health Organization (WHO) estimates that 440 000 cases of MDR-TB occurred in 2008. 8 Of these, only 7% were identifi ed and reported to the WHO, and of the reported cases only a fi fth were S U M M A R Y treated according to WHO standards. 8 Thus, countries seem to be responding slowly to the threat posed by MDR-TB. In April 2009, the WHO convened a ministerial meeting of countries with a high burden of MDR-TB in Beijing, China. 9 This paved the way for the 62nd World Health Assembly to adopt resolution WHA62.15 on the prevention and control of MDR-TB and extensively drug-resistant TB (XDR-TB). The resolution urges Member States to take action on multiple fronts towards achieving universal access to diagnosis and treatment of M/XDR-TB by 2015.
Although much attention is currently being given to M/XDR-TB control, preventive treatment for contacts of MDR-TB patients is not mentioned in the World Health Assembly resolution. A prioritised research agenda for MDR-TB published in 2008 calls for clinical trials or well-designed cohort studies of the effi cacy of several individual drugs and drug combinations in preventive treatment of those persons presumably infected with drug-resistant TB. 10 The attention currently being given to MDR-TB and the call for studies on preventive treatment for contacts of MDR-TB patients might have resulted in new studies since the systematic review performed by Fraser et al. 6 years ago. 6 We therefore conducted a systematic review on the effectiveness of anti-tuberculosis drugs for preventing active TB in persons at risk for developing M/XDR-TB, to collect and assess the evidence for policy making. Because drugs other than INH and RMP that are effective in preventing active TB in persons at risk for developing susceptible, monoor poly-resistant TB might be effective in preventing active TB in persons at risk of developing M/XDR-TB. We therefore conducted a second systematic review in which we evaluated the effectiveness of drugs other than INH and RMP to prevent active TB in persons at risk of developing susceptible, mono-or polyresistant TB.
METHODS
Our main goal was to evaluate the effectiveness of anti-tuberculosis drugs in preventing active TB in persons at risk for developing MDR-TB. Persons at risk of developing active TB are persons exposed to TB infection by being in close contact with a patient with active TB, referred to as 'contacts'. Contacts can be infected with TB (i.e., diagnosed with LTBI), noninfected (negative test for LTBI) or with unknown infection status. We were also interested in the effectiveness of drugs other than INH and RMP in preventing active TB in contacts of non-MDR-TB patients, as this may provide indirect evidence for the effectiveness of these drugs to prevent active TB in contacts of M/XDR-TB patients. We conducted the two systematic reviews following the guidelines of the Cochrane Handbook for Systematic Reviews and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. 11 
Search methods for identification of studies
For the main goal, the approach taken was to update the existing systematic review by Fraser et al. 6 We a ssessed the quality of the review using the AMSTAR tool. 12 As the search strategy was extensive and rigorous methods of data extraction were used, we decided to use the same methods and search strategy for data extraction. We took 1 year overlap with Fraser et al.: 6 as their search ended December 2004, we searched the databases from January 2004 to 19 April 2011. The search strategy used is given in Appendix A.* For our second review on the effectiveness of drugs other than INH and RMP in preventing active TB in persons at risk of developing susceptible, mono-or poly-resistant TB, we included a list of antituberculosis drugs other than INH and RMP in the search strategy. The list contained all drugs mentioned in the guidelines for the programmatic management of drug-resistant TB. 5 In addition, the following key words were used: 'tuberculosis' AND ('latent'
OR 'prevent*' OR 'prophyla*'). The search strategy used can be found in Appendix B. There was no limit on calendar year or language. We included both published and unpublished studies.
For both reviews, we searched the same bibliographic databases as Fraser et al.: CENTRAL, Medline, LILACS and Embase. 6 In addition, we searched the TRIP database (systematic reviews and guidelines; search date 12 May 2011) and BIOSIS Preview (conference abstracts; search date 2 May 2011). The reference lists of identifi ed articles and relevant review articles were checked for additional studies and ongoing controlled trials were searched via the WHO International Clinical Trials Registry Platform (ICTRP; search date 2 May 2011).
Selection of studies
The titles/abstracts of the records identifi ed in the search were independently assessed by two reviewers. References selected by either of the reviewers were included. We evaluated whether the objective of the study was pharmacological treatment/chemotherapy of contacts of (MDR-)TB patients or whether it included information on a cohort of contacts of (MDR-) TB patients who received pharmacological treatment and that reported the outcomes, i.e., whether or not they developed TB. For the review on the effectiveness of other drugs, we evaluated whether the pharmacological treatment of contacts of TB patients was with drugs other than INH or RMP.
In the fi rst phase, we included all publication types, i.e., reviews, letters and comments, as well as all types of primary studies and all languages. The reviews, letters and comments were used for background information and to fi nd additional primary studies. The full texts of potentially relevant studies were reviewed for further eligibility with regard to study design, patients, treatment and outcomes (active pulmonary TB, death from any cause, extra-pulmonary TB, adverse effects). The selection process was performed independently by two reviewers. Consensus was reached by discussion.
Data extraction and analysis
One reviewer (ML) extracted all relevant data items from the included studies, and this was carefully checked by a second reviewer (MvdW). Inconsistencies were discussed to obtain consensus.
The risk of bias of the individual studies was assessed by two reviewers independently. We used the Newcastle Ottawa Scale (NOS) for cohort studies. 13 We planned to do a meta-analysis for studies that were clinically and methodologically homogeneous. However, this was not possible as the studies were clinically and methodologically heterogeneous. The studies were summarised qualitatively. The quality of the evidence was assessed using the GRADE approach. 14 
RESULTS

Update of the review of Fraser et al. on the effectiveness of anti-tuberculosis drugs for preventing active TB in contacts of patients with MDR-TB
Study selection
Of the 1195 results from the January 2004-April 2011 search of CENTRAL, MEDLINE, Embase and LILACS, 19 references were considered potentially relevant ( Figure 1 ). We also identifi ed 30 reviews and assessed these for relevant references. After applying the eligibility criteria to the 19 full-text articles, one study was included. A list with the excluded studies and the reason for exclusion is provided in Table 1 . [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Fraser et al. selected two studies from the search up to December 2004; 6 the total number of included studies was therefore three.
A search of the BIOSIS database resulted in 392 records. The full-text manuscripts of two of these references were retrieved; neither met the eligibility criteria. The TRIP database revealed no additional relevant reviews or guidelines. There were no trials registered in the WHO International Clinical Trials Registry Platform on pharmacological treatment for contacts of active TB patients. We searched the reference lists of the included studies, relevant reviews and (inter)national guidelines, but found no other eligible studies.
Characteristics of the included studies
The characteristics of the included studies are presented in Table 2 . [33] [34] [35] Attamna et al. described the incidence of MDR-TB disease in people who were in close contact with pulmonary MDR-TB patients, and compared the incidence in persons who were offered prophylaxis with those who were not. 35 The study was performed between 1998 and 2006 in Israel, where there were no guidelines for prophylaxis in close contacts of MDR-TB patients. The decision was at the discretion of the treating physician. The duration of follow-up was at least 3 years, with a maximum of 6 years. A total number of 476 close contacts of 78 index patients were identifi ed.
Kritski et al. studied close contacts of retreated MDR-TB patients between 1988 and 1992 in Brazil. 33 In this retrospective study, exposure time was defi ned 2000) was a prospective cohort study in young South African children in household contact with an adult with pulmonary MDR-TB. 34 All infected children and all children aged <2 years who had received no previous treatment or chemoprophylaxis of any kind for TB were offered chemoprophylaxis, classifi ed by the authors as appropriate or inappropriate. Duration of followup was 30 months. In total, 125 contacts of 73 index patients were identifi ed, of whom 14 (11%) were diagnosed with TB. There were 66 infected and 45 noninfected children; 6 children did not return for followup and were excluded from the analysis. Table 3 presents a summary of the risk of bias assessment using the NOS Star template. 13 A study could be awarded a maximum of four stars for Selection, one star for Comparability and three stars for Outcome. The Selection items refer to representativeness of the exposed cohort, selection of the non-e xposed, measurement of exposure and demonstration that the outcome of interest (active TB) was not present at the start of the study. Comparability refers to comparability of exposed and non-exposed, and Outcome to measurement of the outcome, duration of followup and completeness of follow-up.
Risk of bias assessment
In all studies, the untreated contacts were a selected group, because they had received previous TB treatment or chemoprophylaxis, 34 because the decision of treatment was at the discretion of the physician 35 or because the decision of whether or not to treat was not reported and thus unclear. 33 The results of the studies were not adjusted for confounders, which puts them also at high risk of bias.
Effects of the interventions
In one study, there were no TB events in the treated or the untreated group 35 (Table 4) . As a relative risk could thus not be calculated for this study, we decided to 33 ★ ★ ★ ★ ★ Schaaf, 2002 34 ★ ★ ★ ★ ★ ★ * A study could be awarded a maximum of one star for each numbered item within the Selection and Outcome categories and a maximum of two stars can be given for Comparability. For the Selection category, a star was awarded if the exposed cohort was representative, if the non-exposed cohort was drawn from the same community as the exposed cohort, if exposure was ascertained by secure record or by a structured interview, and if it was demonstrated that the outcome of interest was not present at start of study. For Comparability, one star was awarded if the study controlled for the most important factor, another star could be awarded if the study controlled for any additional factor. For Outcome, a star was awarded if the assessment of the outcome was an independent blind assessment or by record linkage, if there was a long enough follow-up for the outcomes to occur, and if there was complete follow-up or if the fact that subjects were lost to follow-up was unlikely to introduce bias. 33 and 5% (95%CI −2 to 11), 34 both in favour of chemoprophylaxis. Schaaf et al. did fi nd a signifi cant risk difference between treated and untreated when assessing confi rmed and probable TB, i.e., 15% (95%CI −27 to −4). Because of the low number of events the CIs were wide. Our other pre-defi ned outcomes -death, extra-pulmonary TB and adverse effectswere not measured in the included studies.
Quality of the evidence
We assessed whether we could upgrade the level of evidence in the GRADE profi le. As there were limitations in study design, inconsistencies and imprecisions among the results, the quality of the evidence could not be upgraded. The quality of the evidence for the effectiveness of chemoprophylaxis to prevent active MDR-TB is thus assessed to be very low.
Review on the effectiveness of anti-tuberculosis drugs other than INH and RMP for preventing active TB in infected contacts of patients with non-MDR-TB
Study selection
Of the 2480 identifi ed records, 238 references were considered potentially relevant (Figure 2) . In a second round of title/abstract selection to identify primary studies, 48 references were identifi ed as primary studies, or the study type was unknown (based on t itle and/or abstract). After applying the eligibility criteria to the 48 full-text articles, none could be included ( Figure 2 , Table 5 ). A search of the BIOSIS database resulted in 392 records. The full-text manuscripts of two of these references were retrieved; neither met the eligibility criteria. The TRIP database was searched and revealed no additional relevant reviews or guidelines.
There were no registered trials on pharmacological treatment for contacts of active TB patients in the WHO International Clinical Trials Registry Platform. A search of the reference lists of relevant reviews and (inter)national guidelines provided no eligible studies.
DISCUSSION
Despite the attention given to MDR-and XDR-TB in recent years, few new publications have dealt with preventive treatment for contacts of MDR-TB patients. Only one additional cohort study has been published since the systematic review of Fraser et al. in 2006. 6 The combined quality of the evidence provided by the three included studies was assessed as very low, which means that any estimate of effect is very uncertain. In this case, it was not even possible to make an estimate of the effect, as the studies were clinically and methodologically too heterogeneous. The risk difference for the prevention of culture-confi rmed TB calculated from the three included studies did not show a signifi cant effect of preventive treatment. The absence of an effect needs to be interpreted with caution, as the sample sizes and number of events were low and the CIs wide.
As discussed in the introduction, the absence of clear evidence to support the prescription of preventive treatment for contacts of MDR-TB patients has resulted in different recommendations being proposed. The ATS and CDC guidelines recommend the administration of preventive treatment, 3 whereas 4, 5 This systematic review found no evidence to support one or the other recommendation.
As information from effectiveness studies provides insuffi cient clear evidence for the development of recommendations for management of contacts of MDR-TB patients, information on the side effects of preventive treatment might be useful. In most studies reporting on adverse effects during preventive treatment for contacts of MDR-TB patients with alternative regimens, side effects were very common. 25, [61] [62] [63] 84 Many contacts discontinued preventive treatment ⎯14/16 (87.5%), 61 13/22 (59.1%), 62 35/48 (72.9%), 63 17/17 (100%), 84 and 7/12 (58.3%) 25 -frequently due to the elevation of liver enzymes. No study reported a death due to preventive treatment.
Given the high prevalence of adverse effects 25, [61] [62] [63] 84 and the low quality of the evidence of the effect of preventive treatment, it would be interesting to know how many contacts develop TB with the same resistance and/or DNA profi le as the index MDR-TB patient. This will of course depend on the likelihood that an infected contact has indeed been infected by the identifi ed index case. In high TB prevalence areas, this is likely to be lower than in low TB prevalence areas. A study in Peru, a high-burden country, showed that of 142 contacts of MDR-TB patients who developed active TB, 129 (90.9%) had MDR-TB but only 77 (59.7%) had the same drug susceptibility testing (DST) results (to both EMB and streptomycin) as their respective index patients. 16 In contrast, in a study in Brazil, fi ve (83%) of six contacts of MDR-TB cases who developed TB, for whom DST results were available, had the same bacterial susceptibility profi les as their index cases. 16, 85 The study of Kritski et al., which is included in this systematic review, reports that, of the 13 isolates of contacts that developed TB, only 6 (46%) had a resistance pattern identical to those of their index case isolate. 33 Four of the 13 isolates (31%) were drug-resistant, but the DST pattern was different from that of the index case, and only three (23%) contacts had isolates susceptible to all drugs. 33 Thus, not every contact who develops TB will have received it from the putative index case. If a contact is actually infected with drug-susceptible TB, preventive treatment with a regimen suitable for contacts of MDR-TB patients would be overtreatment, and would expose the contact to the elevated risk of serious adverse effects. If preventive treatment is guided by the DST pattern of the presumed MDR-TB index case, whereas the contact has been infected by a different MDR-TB index patient, the selected preventive treatment may not be effective.
In conclusion, evidence on the effect of preventive treatment for contacts of MDR-TB patients is limited. The available evidence is not suffi cient to support or reject preventive treatment, and is of very low quality. Evidence-based guideline development for preventive treatment of contacts of MDR-TB patients requires considerably more research, and preferably clinical trials. 
O B J E T I V O :
Las normas internacionales vigentes proponen diferentes recomendaciones sobre el manejo de los contactos de los pacientes con tuberculosis multidrogorresistente (TB-MDR). Con el propósito de contribuir a la formulación de las políticas, se llevaron a cabo dos reseñas bibliográficas a fin de definir las estrategias quimioprofilácticas eficaces dirigidas a los contactos de pacientes con TB-MDR.
M É T O D O :
Se realizó una búsqueda sistemática en las bases de datos Medline, Embase, CENTRAL, LILACS, TRIP y BIOSIS Previews, sobre los estudios de eficacia de los medicamentos antituberculosos en la prevención de la TB activa en las personas con riesgo de contraer la TB-MDR. Esta búsqueda consistió en una actualización de la reseña sistemática llevada a cabo en el 2006, con un método equivalente. Se buscaron además estudios que incluyeran personas con riesgo de presentar TB tras una exposición a pacientes con TB sin MDR y que recibieron tratamiento con medicamentos antituberculosos diferentes a isoniazida o rifampicina.
R E S U LTA D O S :
De las 1195 referencias evaluadas en la actualización, se pudo incluir un estudio adicional. Dado que la reseña inicial incluyó dos estudios, se examinó un total de tres estudios. En un estudio, ninguno de los contactos contrajo la TB, ya sea que hubiesen recibido o no la profilaxis. En los dos estudios restantes, se observaron diferencias no significativas del riesgo de enfermedad activa: 4% (IC95% -3 a 12) y 5% (IC95% -2 a 11), ambos a favor de la quimioprofilaxis. En la nueva reseña se evaluaron 2480 referencias, pero no se pudo incluir ninguna. C O N C L U S I Ó N : La atención que se ha prestado a la TB-MDR en los últimos años no ha dado lugar a publicaciones sobre el tratamiento preventivo de los contactos de pacientes con este tipo de TB. Los datos científicos existentes no son suficientes a fin de respaldar o rechazar la administración del tratamiento preventivo. Además, los datos acumulados en los estudios evaluados presentan una calidad deficiente.
R É S U M É R E S U M E N
